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Follicular lymphoma patients display heterogeneous overall
survival and variable risk of transformation.  Recent studies
have highlighted the role of the microenvironment. The
contribution of microvessel density to follicular lymphoma
survival remains controversial. We used a quantitative
tumor mapping approach to determine whether the degree
of vascularization correlated with outcome in a uniformly
treated cohort. Whole-tissue sections of diagnostic biopsies
from 84 cases were stained for CD34 and tumor-to-vessel-
distance that encompassed 90% of the tumor (TVD90) was
determined using image analysis. Twenty-one cases with
lower TVD90 showed inferior overall survival (P=0.0001) and
high risk of transformation (P=0.01). These cases significant-
ly correlated with increased Lymphoma-Associated
Macrophages (χ2=0.025). In multivariate analysis
macrophages content, IPI and TVD90 were independent pre-
dictors of overall survival (P=0.05, P=0.001 and P=0.01,
respectively) and IPI and TVD90 predicted risk of transforma-
tion (P=0.008 and P=0.08, respectively). Increased angiogen-
esis is an independent marker of inferior survival and may
promote transformation. 
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ABSTRACT
Introduction
The clinical course of follicular lymphoma (FL) is unpre-
dictable, with median survivals in the range of ten years.
Histological transformation, usually into diffuse large B-cell
lymphoma (DLBCL), heralds aggressive clinical behavior and
is typically associated with inferior survival. A recent popula-
tion based analysis from the British Columbia Cancer Agency
(BCCA) including 600 newly diagnosed FL patients showed
an annual risk of transformation (RT) of 3% continuing
beyond 15 years of follow up.1 The treatment of FL patients
is markedly heterogeneous, as no optimal treatment approach
has yet been established. The number of prior treatments,
tumor burden, advanced-stage and high-risk FLIPI or IPI are
the only established clinical features associated with RT.2
Importantly, none of the clinical variables consistently predict
RT. Thus, biological predictors of transformation are needed
to individualize therapy and better assess risk. Angiogenesis
plays a crucial role in oncogenesis, promoting growth and
progression of both solid and hematologic tumors.3,4 The
acquisition of an angiogenic phenotype, referred to as the
“angiogenic switch”, allows the formation of neovessels that
are vital for tumor growth.5 This "angiogenic switch" results
not only from interactions between vessels and cancer cells,
but also involves non-neoplastic cells in the microenviron-
ment, including macrophages. Microvessel density (MVD)
has, in some tumor types, shown a correlation with survival.
Yet, in FL the impact of MVD on prognosis is controversial.6,7
In most series the number of cases studied is small and/or the
therapies markedly heterogeneous, both of which preclude
definitive conclusions. In this study, we report the clinical sig-
nificance of MVD in uniformly treated FL patients using a
quantitative tumor mapping approach.
Design and Methods
Patients
Between July 1987 and May 1993, patients with FL were enrolled in
a single institution phase II trial using BP-VACOP chemotherapy
(bleomycin, cisplatin, etoposide, doxorubicin, cyclophosphamide, vin-
cristine and prednisone) followed by involved field irradiation to sites
of original nodal involvement. Patients aged 16 to 61 years, with
newly diagnosed, treatment-naïve and advanced-stage disease,











radioencompassable disease, or bulk of 10 cm or more in maxi-
mum diameter at any individual tumor site were included.
Approval to this study was given by the University of British
Columbia BCCA Research Ethics Board. All biopsies were
reviewed and classified according to the 2008 WHO classifica-
tion.8 Transformation was defined as biopsy proven or clinically
diagnosed aggressive lymphoma as described previously.1
Histology and immunohistochemistry
Of the 126 cases of FL, 84 had formalin-fixed paraffin blocks
with adequate material remaining in the block to be used for
whole sections. Immunohistochemistry was performed routinely
for CD20 (L26, dilution 1:800, Dako®, Carpentaria, California,
USA) and CD34 (QBEend10, dilution 1:30, Dako®, Carpentaria,
California, USA) using a Dako® autostainer and the EnVision
polymer detection system. CD68+ cell content biomarker,
Lymphoma-Associated Macrophages (LAM) data were based on a
previous study.9
Microvessel density and follicle size 
Images of whole sections were stained for CD34 and captured
using a cooled CCD camera, a motorized stage and customized
NIH software.10 Thresholding was applied to identify CD34 posi-
tive objects. The motorized stage allowed for tiling of adjacent
microscopic fields, thereby allowing reassembly of the entire
tumour section at high resolution (Figure 1). High-resolution
images of tumor vasculature over the entire whole-sections of
each case defined “distance maps”. The distance from each tumor
cell in the tissue to the nearest CD34+ pixel was measured auto-
matically and the mean of distances of all cells to the nearest vessel
in the whole section was used to calculate the tumour-to-vessel
distance that encompassed 90% of the tumor (TVD90). Average
follicle size per case was visually ranked according to the follow-
ing groups: 0 - loss of follicular pattern; 1 - small follicles (dense
staining), and 2 - large follicles (sparse staining).
Statistics and survival analysis
Overall survival (OS) was defined as the interval from date of
diagnosis until death from any cause. Survival estimates were cal-
culated using the Kaplan-Meier method11 and multivariate analysis
using the proportional-hazards regression model.12
Results and Discussion
There were 84 suitable cases for analysis. The median
follow up of the living patients was 14.3 years and 20
patients underwent transformation. The IPI was signifi-
cant for both OS and risk of transformation (RT) in uni-
variate analysis (P=0.0001 and P=0.01, respectively).
Estimated 10-year OS and RT for all patients were 65%
and 20%, respectively. TVD90 ranged from 50.3 to 144
microns (median 78.4) and these data were divided into
quartiles. In univariate analysis the quartile (21 cases) with
low TVD90 (i.e. high MVD) showed inferior OS (P=0.0001)
and an increased RT (P=0.01) (Figure 2). These 21 cases are
defined as Low TVD90 while the three other quartiles (63
cases) are defined as High TVD90. Clinical characteristics
are summarized in Table 1. As most cases showed a dis-
tinct perifollicular pattern, we correlated TVD90 with folli-
cle size in each case. There was a significant association
between low TVD90 and small follicle size (χ2, P=0.01).
Low TVD90 also correlated with younger age (χ2, P=0.034),
increased IPI (χ2, P=0.01) and increased CD68+
macrophages (χ2, P=0.025). In univariate analysis, TVD90
and IPI are significant for both OS and RT, but not age or
follicle size. In this cohort, CD68+ macrophages predicted
OS (P=0.0004), but not RT (P=0.38). In a Cox’s model
including TVD90, CD68+ and IPI, all three markers were
independent variables for OS, TVD90 (RR=2.5, 95%
CI=1.1-5.0, P=0.01), CD68+ (RR=2.2, 95% CI=1.0-5.0,
P=0.05) and IPI (RR=2.9, 95% CI=1.5-5.5, P=0.001).
Finally, in a Cox’s model for RT, only IPI significantly pre-
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Figure 1. High-resolution image of a CD34 immunostained section
allowing the identification of tumor vasculature across the entire
section.
Figure 2. Tumor-to-vessel distance including 90% of malignant cells




















































dicted RT (P=0.008), while TVD90 was of borderline signif-
icance (P=0.08). Angiogenesis plays a crucial role in the
growth and progression of human solid tumors.13 In most
tumor types, increased MVD correlates with increased
disease progression and decreased survival. Similar results
have been reported in hematopoietic tumors, including
multiple myeloma and lymphoma.3,4,14,15 In murine lym-
phoma models and in lymphoma patients, circulating
endothelial cells and serum vascular endothelial growth
factor (VEGF) levels appear to correlate with lymphoma
volume and increased angiogenesis.16,17 In contrast, previ-
ous studies of MVD in FL have resulted in conflicting
results. Koster et al. showed increased MVD to be associ-
ated with a more favorable OS in a series of 36 uniformly
treated patients given CVP and interferon (IFN) α2b fol-
lowed by IFN maintenance.6 In a later report, Jorgensen et
al. analyzed 107 FL cases with heterogeneous treatments
and found increased interfollicular MVD predicted inferior
OS and increased transformation to DLBCL.7 In both stud-
ies, MVD was calculated using quantification of focal
“vessel hot spots” within the tumor. In FL, however, the
vessels show a heterogeneous distribution. Therefore, in
order to avoid a scoring bias, we studied whole sections of
FL biopsies and quantified automatically the average dis-
tance from CD34 stained vessel that included 90% of
tumor cells: TVD90. We believe this is a more accurate
measurement of vessel density. Because of vessel predom-
inance within the interfollicular and perifollicular areas,
TVD90 was correlated with the average size of the follicles
in each case. Interestingly, cases with low TVD90 correlat-
ed with small sized follicles although follicle size itself did
not affect survival or risk of transformation. 
In the current study, all 84 patients were treated uni-
formly with multi-agent chemotherapy and radiation,
while in the series by Koster et al. all 36 patients were
treated with CVP chemotherapy and IFN followed by IFN
maintenance. In addition to the difference in cohort size,
different therapeutic regimens may explain the contradic-
tory results. IFN has both immunomodulatory and anti-
angiogenic effects and thus may have been more effective
in tumors with increased MVD.18 Radiation has been
shown to induce tumor cells to secrete cytokines capable
of inhibiting apoptosis in endothelial cells, thereby dimin-
ishing treatment response.19,20 It remains possible that this
treatment modality influenced survival and transforma-
tion risk in our study. 
It is well known that angiogenesis in cancer is critically
influenced by the local tumor microenvironment.21 Using
the same uniformly treated cohort, we previously showed
that increased numbers of Lymphoma-Associated
Macrophages (LAM) is associated with adverse outcome.9
Similar to solid tumor-associated macrophages, these LAM,
possibly originating from bone marrow derived myeloid
cells, may be attracted by hypoxia and tumor-derived
chemotactic factors and show a distinct phenotype that pro-
motes angiogenesis.22-24 Consistent with this hypothesis, we
show a significant association between TVD90 and LAM. 
In summary, this study confirms the clinical relevance of
increased angiogenesis affecting both FL survival and
transformation risk in a series of advanced-stage FL
patients uniformly treated with chemotherapy and radio-
therapy. These findings suggest MVD as a useful biomark-
er in initial therapeutic decisions of patients with FL, and
thus may provide a rationale for trials of anti-angiogenic
therapy in FL patients with increased MVD.
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Table 1. Distribution of clinical and pathology variables between high
TVD90 and low TVD90 cases.
Feature                # Patients with  # Patients with   Total (%)     P value
                               Low TVD 90       High TVD 90                          (χ2)
                                      (%)                      (%)                    
Number                          21 (25)                   63 (75)             84 (100)            -
Clinical Features                                                                                                 
Median age (y)                  39                            46                        -               0.034
Female (%)                        52                            48                        -                 0.63
Median follow up (y)      13.9                         14.3                       -                 0.83
IPI Group 1 (0/1)           8 (38)                    45 (71)              62 (61)         0.01*
Group 2 (2/3)              13 (62)                   17 (27)              39 (38)              
Group 3 (4/5)                0 ( 0)                      1 (2)                  1 (1)                
BM Involvement (%)   14 (66)                   28 (44)              42 (50)          0.13
Treatment Response                                                                                          
CR                                   8 (38)                    39 (62)              47 (56)        0.08**
PR                                  13 (62)                   23 (36)              36 (43)              
NR                                    0 (0)                       1 (2)                  1 (1)                
Pathology Features                                                                                             
FL Grade                                                                                                               
Grade 1                         17 (80)                   49 (78)              66 (78)       0.76***
Grade 2                          4 (20)                    10 (16)              14 (17)              
Grade 3                           0 (0)                       4 (6)                  4 (5)                
Large follicles (%)         1 (5)                     20 (32)              21 (25)          0.01
Increased CD68+          5 (24)                      4 (7)                     9               0.025
cells (%)                               
Transformation (%)       8 (38)                    12 (19)              20(24)          0.076
IPI: International Prognostic Index score, BM: bone marrow, CR: complete remission,
PR: partial remission, NR: no response; *IPI group 1 vs. 2/3 **CR vs. PR/NR ***Grade
1 vs. 2/3A.
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